Qeen Biotechnologies specializes in the biomanufacturing of bacteriophages using GMP-certified processes to produce high-quality therapeutic solutions for bacterial infections in agriculture, human health, and veterinary applications. The company addresses the challenge of antibiotic resistance by providing non-toxic, cost-effective alternatives that enhance bacterial control across various industries.
Funding
$145.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of antibiotic-resistant bacteria poses a significant threat to human health, agriculture, and animal health, requiring new strategies for controlling bacterial infections. Traditional antibiotics often have broad-spectrum effects, disrupting beneficial microbial communities and driving the evolution of resistance. Current biomanufacturing processes may not consistently deliver high-quality, cost-effective bacteriophage-based therapeutics.
Solution
Qeen Biotechnologies specializes in the GMP-certified biomanufacturing of bacteriophage-based solutions designed to combat bacterial infections across various sectors. The company offers tailored bacteriophage products for applications in agri-food, human health, animal health, and nutraceuticals, providing alternatives to traditional antibiotics. Their bacteriophages target specific bacteria, offering a more precise and less disruptive approach to bacterial control. By adhering to rigorous scientific and regulatory standards, Qeen Biotechnologies ensures the purity, potency, and safety of its bacteriophage products.
Target Audience
The primary customers are pharmaceutical companies, agricultural businesses, veterinary practices, and nutraceutical manufacturers seeking targeted antibacterial solutions.
Features
- GMP-certified biomanufacturing process ensuring high-quality bacteriophage production
- Tailored bacteriophage solutions for specific bacterial targets in diverse applications
- Advanced quality control measures, including analytical capabilities and testing protocols
- Expertise in optimizing phage production for therapeutic applications
- Downstream processing capabilities for bacteriophage purification and formulation
- Cell banking services for maintaining consistent phage stocks
- Regulatory consulting services to support product development and compliance
- Phage characterization services to determine host range, efficacy, and stability